Aurobindo pharma targeting us$ 2 billion turnover in fy15
The Hyderabad based company is aiming to achieve US$ 2 billion revenue.
Hyderabad, August 5, 2014: Aurobindo Pharma aims to achieve US$ 2 billion turnover in the current financial year. The company is also looking at securing nine more injectables approvals from USFDA.
The company has said in its annual report that it is looking at leveraging its large state-of-the-art manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, the company aims to achieve US$ 2 billion revenues by 2014-15.
It may be noted here that the consolidated revenue from operations was higher over the last year by 38.3 per cent at Rs 8,100 crore (US$ 1.5 billion) during 2013-14.
The company also said that it is gearing for meaningful growth in the medium term and has around 45 files under review with USFDA. The company hopes to file nine more in 2014-15 and another 30 in 2015-16.